Table 3.
Grade 3 to 5 AEs at Least Possibly Related to Treatment in Treated Patients Using CTCAE (version 3) Criteria
| AE | No. (%) | ||
|---|---|---|---|
| ECF-C (n = 67 evaluable) | IC-C (n = 73 evaluable) | FOLFOX-C (n = 73 evaluable) | |
| Hematologic | 36 (53) | 43 (59) | 34 (46) |
| Neutropenia | 33 (49) | 37 (51) | 31 (43) |
| Leukocytopenia | 9 (13) | 16 (22) | 12 (16) |
| Anemia | 5 (7) | 10 (13) | 5 (7) |
| Thrombocytopenia | 3 (4) | 6 (8) | 2 (3) |
| Lymphopenia | 5 (7) | 8 (11) | 2 (3) |
| Nonhematologic | 49 (73) | 56 (77) | 48 (66) |
| Constitutional symptoms | 9 (13) | 15 (21) | 12 (16) |
| Dermatologic | 12 (17) | 8 (11) | 16 (22) |
| GI | 21 (31) | 30 (41) | 16 (22) |
| Infection | 9 (12) | 6 (7) | 5 (7) |
| Metabolic | 12 (18) | 25 (34) | 19 (26) |
| Neurologic | 10 (15) | 2 (3) | 12 (16) |
| Pain | 6 (8) | 2 (3) | 2 (3) |
| Pulmonary | 3 (4) | 2 (3) | 0 (0) |
| Vascular | 5 (7) | 7 (9) | 3 (4) |
| Death (not CTCAE defined) | 3 (4) | 0 (0) | 0 (0) |
Abbreviations: AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; ECF-C, epirubicin, cisplatin, and fluorouracil plus cetuximab; FOLFOX-C, oxaliplatin, leucovorin, and fluorouracil plus cetuximab; IC-C, irinotecan and cisplatin plus cetuximab.